Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells

This publication has 34 references indexed in Scilit:

• The Effect of Statins in Colorectal Cancer Is Mediated Through the Bone Morphogenetic Protein Pathway
  Gastroenterology, 2007
• BMP-induced growth suppression in colon cancer cells is mediated by p21WAF1 stabilization and modulated by RAS/ERK
  Cellular Signalling, 2007
• Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells
  Nature, 2006
• Bone morphogenetic protein signaling and growth suppression in colon cancer
  American Journal of Physiology-Gastrointestinal and Liver Physiology, 2006
• Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy
  Annual Review of Medicine, 2006
• Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas
  Oncogene, 2005
• Smad pathway‐specific transcriptional regulation of the cell cycle inhibitor p21^WAF1/Cip1
  Journal of Cellular Physiology, 2005
• The 18q21 region in colorectal and pancreatic cancer: independent loss of DCC and DPC4 expression
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2000
• Proteasome-Dependent Regulation of p21WAF1/CIP1Expression
  Biochemical and Biophysical Research Communications, 1996
• Brefeldin A Is a Potent Inducer of Apoptosis in Human Cancer Cells Independently of p53
  Experimental Cell Research, 1996